HLA-C and neoplasm: In summary these findings indicate that OKI-179 may prime the tumor response by enhancing tumor cell immunogenicity, increase MHC on multiple antigen presenting cell subsets, increase T cell frequencies in the blood while also altering Treg to cytotoxic T cell ratios.